Coherus BioSciences (CHRS) surges on FDA Udenyca delivery system approval
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street futures fall as oil, Treasury yields rise on Iran tensions
- Oil prices steady as traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- Berkshire’s Abel says data centers are energy opportunity
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Coherus (CHRS) Announces FDA Approval of UDENYCA ONBODY
December 26, 2023 4:03 PM ESTCoherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) approved UDENYCA ONBODY, the company's on-body injector (OBI) presentation of UDENYCA® (pegfilgrastim-cbqv), a pegfilgrastim biosimilar administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia.
The on-body injector for UDENYCA is the result of years of significant investment in research and development to bring forward a novel and proprietary device that provides patients... More
